Melanoma Clinical Trials in Portland

Showing 101-120 of 142 trials

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

NCT01636882

This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 intratumoral injections will be made available.

Melanoma

Viralytics16 participantsStarted Jul 2012

Park Ridge, Illinois, United States • Portland, Oregon, United States • Dallas, Texas, United States +1 more locations

COMPLETEDPhase 2< 1 mile

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551

The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).

Malignant Melanoma

Viralytics57 participantsStarted Dec 2011

La Jolla, California, United States • San Francisco, California, United States • Miami Beach, Florida, United States +7 more locations

COMPLETED< 1 mile

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

NCT01415167

The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.

Metastatic Renal Cell CarcinomaMetastatic Melanoma

Prometheus Laboratories1,690 participantsStarted Aug 2011

Tucson, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +42 more locations

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Melanoma Trials in Other Cities

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Development and Validation of a New Digital Dermatoscope in the United States

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Other Conditions in Portland